Cargando…
A novel sustained‐release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers
The strict intake regimen of cysteamine bitartrate formulations, associated with side effects, is a concern for the treatment compliance in cystinosis therapy. Therefore, there is a need for a cysteamine formulation with an improved pharmacokinetic profile. This study investigated the pharmacokineti...
Autores principales: | Berends, Cécile L., Pagan, Lisa, van Esdonk, Michiel J., Klarenbeek, Naomi B., Bergmann, Kirsten R., Moerland, Matthijs, van der Wel, Vincent, de Visser, Saco J., Büller, Hans, de Loos, Frans, de Vries, Wouter S., Waals, Hans, de Leede, Leo G. J., Burggraaf, Jacobus, Kamerling, Ingrid M. C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992283/ https://www.ncbi.nlm.nih.gov/pubmed/33764642 http://dx.doi.org/10.1002/prp2.739 |
Ejemplares similares
-
Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients
por: Klank, Sabrina, et al.
Publicado: (2023) -
Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to “A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis”)
por: Langman, Craig B.
Publicado: (2023) -
Quality of Life is Improved and Kidney Function Preserved in Patients with Nephropathic Cystinosis Treated for 2 Years with Delayed-Release Cysteamine Bitartrate
por: Langman, Craig B., et al.
Publicado: (2014) -
A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis
por: Armas, Danielle, et al.
Publicado: (2018) -
Cysteamine–bicalutamide combination therapy corrects proximal tubule phenotype in cystinosis
por: Jamalpoor, Amer, et al.
Publicado: (2021)